Compare Organon & Co. Common Stock (OGN) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Invesco Preferred ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Invesco Preferred ETF trades at $9.93 (market cap $3.58B). The key difference: Organon & Co. Common Stock and Invesco Preferred ETF are close in size by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Invesco Preferred ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Invesco Preferred ETF for 96 Days on average.
| OGN | PGX | |
|---|---|---|
Market Cap | $3.62B | $3.58B |
Volume | 2,892,999 | 10,976,352 |
Sector | Health | — |
52-Week High | $13.81 | $11.61 |
52-Week Low | $5.70 | $9.95 |
Typical Hold Time | 0 Days | 96 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
PGX trades at $9.98 with a modest 0.3% daily gain, though technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The stock faces significant resistance at $10, which also serves as multiple support levels. Recent corporate actions include scheduled dividends of $0.06 per share for H2-2026, providing income potential for shareholders.
The outlook remains cautious given the bearish technical setup and lack of available fundamental data. While dividend payments offer some investor appeal, the absence of key valuation metrics and financial ratios creates uncertainty about the company's underlying business performance and competitive positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
